

Supplementary Table 5 Hazards ratios of rs3218536 by study and ER and PR status\*

PR status	Negative			Positive		
	Study	No.Total	No.deaths	HR <sup>†</sup> (95% CI)	No.Total	No.deaths
ABCFS	327	88	1.22 (0.72-2.07)	752	148	1.11 (0.69-1.77)
CNIO-BCS	57	5	1.09 (0.13-9.06)	82	0	NA
HABCS	35	4	2.18 (0.42-11.22)	372	49	0.58 (0.18-1.87)
PBCS	626	134	1.58 (1.00-2.49)	668	55	0.95 (0.43-2.13)
SBCS	93	29	1.36 (0.71-2.61)	152	29	1.82 (0.81-4.09)
SEARCH	728	182	1.18 (0.84-1.65)	1465	202	1.00 (0.70-1.46)
<b>Pooled</b>	1866	442	1.31 (1.04-1.63)	3491	483	1.06 (0.82-1.36)

  

ER status	Negative			Positive		
	Study	No.Total	No.deaths	HR <sup>†</sup> (95% CI)	No.Total	No.deaths
ABCFS	367	104	1.02 (0.59-1.76)	714	132	1.28 (0.81-2.02)
CNIO-BCS	35	2	NA	105	3	2.12 (0.28-15.82)
HABCS	33	5	2.29 (0.51-10.38)	395	52	0.50 (0.16-1.61)
PBCS	434	99	1.35 (0.81-2.26)	866	91	1.11 (0.60-2.07)
SBCS	102	28	0.68 (0.21-2.22)	299	66	1.97 (1.19-3.25)
SEARCH	624	158	1.16 (0.79-1.70)	2368	337	1.26 (0.98-1.63)
<b>Pooled</b>	1595	396	1.14 (0.88-1.47)	4747	681	1.29 (1.07-1.56)

\* PR: progesterone receptor; ER: estrogen receptor; NA: not available; total numbers differ because of missing PR and ER status

† adjusted for age and accounting for left-censoring time; pooled results adjusted for study